


(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/17531 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/505** (74) Agent: **FRIEDMAN, Mark, M.**; Beit Samueloff, Haomanim Street 7, 67897 Tel Aviv (IL).
- (21) International Application Number: **PCT/IL99/00441**
- (22) International Filing Date:  
9 September 1999 (09.09.1999)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (71) Applicant (*for all designated States except US*): **HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD.** [IL/IL]; Kiryat Hadasah, 91120 Jerusalem (IL).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **PINES, Mark** [IL/IL]; Pinsky Street 12B, 76308 Rehovot (IL). **VLODAVSKY, Israel** [IL/IL]; Arbel Street 34, 90805 Mevasseret Zion (IL). **NAGLER, Arnon** [IL/IL]; Sderot Herzl 46, 74381 Jerusalem (IL).
- Published:  
— *With international search report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**WO 01/17531 A1**(54) Title: **PROMOTION OF WOUND HEALING**

(57) Abstract: A promotor of wound healing and an inhibitor of formation of a urethral stricture, particularly following surgical intervention or infection in the area. Specifically, the most preferred compound of the present invention, Halofuginone, can be used to prevent collagen deposition from occurring within the lumen of the urethra after such trauma, thereby inhibiting urethral stricture formation. Halofuginone, and related compounds, are also useful for the promotion of wound healing after trauma, for example after surgery.